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Pmpaired Insulin Sensitivity as an
ndependent Risk Factor for Mortality in
atients With Stable Chronic Heart Failure
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ondon, United Kingdom; Berlin, Germany; Wroclaw, Poland; and Sydney, Australia
OBJECTIVES The aim of this study was to determine the significance of insulin resistance as an independent
risk factor for impaired prognosis in patients with chronic heart failure (CHF).
BACKGROUND In CHF, impaired insulin sensitivity (SI) indicates abnormal energy metabolism and is related
to decreased exercise capacity and muscle fatigue. The relationship between insulin resistance
(i.e., low SI) and survival in patients with CHF has not been established.
METHODS We prospectively studied 105 male patients with CHF due to ischemic (63%) or non-
ischemic (37%) etiology. All patients were in clinically stable condition (age 62 1 year, New
York Heart Association [NYHA] functional class 2.6  0.1, left ventricular ejection fraction
[LVEF] 28  2%, peak oxygen uptake [VO2] 18.2  0.7 ml/kg/min). Insulin sensitivity was
assessed from glucose and insulin dynamic profiles during an intravenous glucose tolerance
test using the minimal model technique.
RESULTS During a mean follow-up period of 44  4 months, 53 patients (50%) died. Patients with SI
below the median value (median: 1.82 min1 · U · ml1 · 104; n  52) had worse survival
(at two years 61% [range 47% to 74%]) than patients with SI above the median value (n 
53; at two years 83% [range 73% to 93%]; risk ratio [RR] 0.38, 95% confidence interval [CI]
0.21 to 0.67; p 0.001). Both patient groups were similar in terms of age, NYHA functional
class, and body composition parameters (dual-energy X-ray absorptiometric scan; p  0.2),
but patients with a lower SI had a lower LVEF (24  2% vs. 33  3%) and peak VO2 (16.8
 1.0 ml/kg/min vs. 19.7  1.0 ml/kg/min; both p  0.05). On univariate Cox analysis,
higher SI predicted better survival (RR 0.56, 95% CI 0.35 to 0.89; p  0.015). On stepwise
multivariate analysis, SI predicted mortality independently of other variables.
CONCLUSIONS In patients with CHF, lower SI relates to higher mortality, independent of body composition
and established prognosticators. Impaired SI may have implications in the pathophysiology of
CHF disease progression. Therapeutically targeting impaired insulin sensitivity may poten-
tially be beneficial in patients with CHF. (J Am Coll Cardiol 2005;46:1019–26) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.093the American College of Cardiology Foundation
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phronic heart failure (CHF) is a leading cause of both
orbidity and mortality in Western society with increas-
ng prevalence and health care costs. It has been shown
hat impaired whole-body insulin sensitivity (SI) com-
only occurs in CHF, independent of ischemic etiology
1). As part of the metabolic syndrome, insulin resistance
s associated with arteriosclerotic cardiovascular disease,
ncluding ischemic CHF. It has been shown, however,
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005, accepted February 14, 2005.hat also patients with a non-ischemic etiology of CHF
ave impaired SI (2,3) and the degree of insulin resistance
orrelates with the degree of heart failure (1). Increasing
See page 1027
vidence suggests a relationship between impaired glucose
etabolism and CHF. Diabetes mellitus has been shown to
e a predisposing factor for development of CHF (4,5). In
he Studies Of Left Ventricular Dysfunction (SOLVD),
iabetes was an independent predictor of mortality and
orbidity in CHF patients (6). In large heart failure trials,
iabetes mellitus has a prevalence of 20% to 25% (7–10).
he clinical significance of insulin resistance in CHF is not
nown. However, insulin resistance may occur prior to type
diabetes mellitus being diagnosed, so the prevalence of
nsulin resistance is likely much higher. If insulin resistance
s pathophysiologically linked with CHF and progresses in
arallel with the degree of CHF (1,11), one could hypoth-
size insulin resistance to be a prognostic factor.
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Insulin Resistance and Survival in CHF September 20, 2005:1019–26The aim of present study was to investigate in a cohort of
atients with CHF whether the presence of insulin resis-
ance in CHF is an independent risk factor for impaired
rognosis. Regional fat and lean tissue composition (impor-
ant factors in insulin resistance) were also measured.
ETHODS
tudy population. We prospectively studied 105 male
HF patients with ischemic (63%) or non-ischemic (37%)
tiology between May 1993 and February 2001. The diag-
osis of CHF was based on clinical evidence of heart failure
ith shortness of breath, symptomatic exercise limitation,
nd peripheral edema with a disease history of at least six
onths. In all patients, evidence of left ventricular func-
ional impairment by radionuclide ventriculography and/or
chocardiography was present. All patients were treated as
linically indicated with angiotensin-converting enzyme
ACE) inhibitors or angiotensin II receptor antagonists
85%), diuretics (87%), beta-blockers (20%), digitalis (33%),
r aspirin and/or warfarin (75%). Patients were clinically
table at the time of SI assessment, with no clinical evidence
f decompensated heart failure, such as raised jugular
enous pressure, ascites, or hepatomegaly. At the time of the
tudy, none of the patients were diagnosed with diabetes
according to World Health Organization criteria) or had
ntidiabetic treatment. Female patients were excluded from
he study to prevent influences from gender and related
actors such as hormone replacement therapy.
All patients gave written, informed consent, and the
tudy was approved by our local ethics committees.
ssessment of SI. All participants underwent intravenous
lucose tolerance testing (ivGTT), as previously described
12). The ivGTT was performed under standardized con-
itions in a metabolic day ward starting in the morning
etween 8:00 AM and 9:00 AM following overnight fasting
fter at least 20 min of supine rest. A glucose bolus (50%
olution) was administered intravenously at a dose of 0.5
/kg body weight. All blood samples were immediately
rocessed and stored at 80°C until analysis of glucose and
nsulin. From the glucose and insulin dynamic profiles, the
I index was calculated using the minimal model approach
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BMI  body mass index
CHF  chronic heart failure
CI  confidence interval
DEXA  dual-energy X-ray absorptiometry
ivGTT  intravenous glucose tolerance test
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RR  risk ratio
SI  insulin sensitivity
VO2  oxygen uptakeccording to Bergman et al. (13). The relatively high glucose mose (0.5 vs. 0.3 g/kg) we use enables evaluation of SI by the
inimal model, without the need for augmentation of
lasma insulin concentrations by tolbutamide or insulin
njection. We have validated SI estimates derived using this
pproach in patients with CHF against the euglycemic
lamp reference method (14). Insulin sensitivity—the in-
erse of insulin resistance—is defined as the fraction of the
lucose distribution space cleared per minute by insulin-
ependent glucose disposal relative to the concentration of
nsulin and is expressed in min1 · U · ml1 · 104. Insulin
oncentrations during ivGTT were expressed as the incre-
ental area under the concentration profile, calculated using
he trapezium rule.
ody composition. In all subjects, body mass index (BMI)
as calculated as the ratio of weight (kg) and squared height
m2). For body composition assessment, dual-energy X-ray
bsorptiometry (DEXA) was performed in 89 of the pa-
ients by using a Lunar DPX (Lunar Corp., Madison,
isconsin). Total body scans were analyzed to obtain total
nd regional (legs, arms, and trunk) measurements of fat
nd lean tissue. Precision of total and regional assessments
as 2% for lean tissue and 5% for fat tissue (15). Fat
ass of the trunk, termed as “central fat mass,” includes
oth visceral and subcutaneous fat of this anatomic region.
he sum of fat mass of the legs and arms was termed as
peripheral fat mass.” The distribution of fat mass was
alculated as the ratio of central fat mass/peripheral fat
ass.
xercise test and follow-up. A maximal cardiopulmonary
readmill exercise test was performed for clinical character-
zation (modified Bruce protocol), using a respiratory mass
pectrometer (Amis 2000, Odense, Denmark) and a stan-
ard inert gas dilution technique for assessment of peak
xygen uptake (VO2), as described previously (16).
All patients received follow-up by the Royal Brompton
ospital Heart Failure and Cardiomyopathy Clinic.
ollow-up was by outpatient assessment and from informa-
ion obtained by the Office of National Statistics, where all
atients had been flagged for death. No patient was lost
uring follow-up.
tatistical analyses. All results are presented as the mean
alue  SEM. The unpaired Student t test was used to
ompare mean values between groups. Distributions for
iochemical variables were evaluated for normality using the
olmogorov-Smirnov test, and logarithmic transformation
as applied where necessary to allow a parametric statistical
pproach. Insulin sensitivity was square-root transformed in
ccordance with our previous analysis of the distribution
haracteristics of model-derived variables (17). A probabil-
ty value of 0.05 was considered statistically significant.
ox proportional hazards analysis was employed to assess
he association of variables to survival. Stepwise multivariate
nalysis was performed with all parameters that had a p 
.1 in the univariate analysis. The risk ratio (RR) and 95%
onfidence interval (CI) for risk factors are given. A com-
ercially available statistical software program was used
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alifornia).
ESULTS
atient characteristics and follow-up. We studied a total
f 105 CHF patients. Patient characteristics at baseline are
iven in Table 1. The mean follow-up period in these
atients was 44 4 months. During this period, 53 patients
50%) died after 4 to 3,319 days (mean 775  106 days,
edian 527 days). The mean follow-up period of the 52
urvivors was 1,905  153 days (range 396 to 3,719 days,
edian 1,474 days). The cumulative mortality of the pa-
ients was 22% at 12 months (95% CI 14% to 30%), 28% at
4 months (95% CI 19% to 36%), and 40% at 36 months
95% CI 30% to 50%).
Patients who died during follow-up had a similar age,
MI, and left ventricular ejection fraction (LVEF) com-
ared with patients who did not die. Patients who died
ad a smaller regional lean tissue mass at the arms and
egs and a trend toward lower total fat mass. These
atients had also a higher mean NYHA functional class
0.5) and lower peak VO2 (21%, both p  0.004).
nsulin sensitivity was lower in these patients compared
able 1. Clinical and Anthropometric Characteristics of 105 Pati
atients Who Died During the Follow-Up Period and Those W
Parameter
All CHF Patients
(n  105)
ge (yrs) 62  1
tiology
Ischemic cardiomyopathy 66 (63%)
Dilated cardiomyopathy 39 (37%)
YHA functional class (mean) 2.6  0.08
ystolic blood pressure (mm Hg) 116  2.0
iastolic blood pressure (mm Hg) 72  1.2
eak VO2 (ml/kg/min) 18.2  0.7
xercise time (s) 424  22
VEF (%) 28  2
odium (mmol/l) 137  0.3
reatinine (mol/l) 129  6.2
ric acid (mol/l) 472  15
emoglobin (g/dl) 13.4  0.1
holesterol (mmol/l) 5.13  0.11
eight (kg) 73.8  1.6
ody mass index (kg/m2) 24.7  0.4
otal body fat tissue (kg)* 18.4  0.86
entral fat tissue (kg)* 10.3  0.49
eripheral fat tissue (kg)* 7.08  0.40
atio central/peripheral fat* 1.56  0.05
otal lean tissue (kg)* 52.4  0.53
eripheral lean tissue (kg)* 22.1  0.45
asting glucose (mg/dl) 104  3.2
asting insulin (mU/l) 13.0  0.93
ncremental insulin area (min · mU/l) 4,081  314
nsulin sensitivity (min1 · U · ml1 · 104) 2.53  0.26
Dual-energy X-ray absorptiometric scan in 89 subjects (46 died, 43 survived). Data
tatistically significant results.
CHF  chronic heart failure; LVEF  left ventricular ejection fraction; NYHAith the surviving patients (42%, p  0.002). Detailed linical and body composition characteristics of both
roups are shown in Table 1.
In all patients, mean SI was 2.53  0.26 min
1 · U ·
l1 · 104. According to median SI (1.82 min
1 · U ·
l1 · 104), we dichotomized the CHF patients into two
ubgroups. Patients with SI below the median value (n  52)
ad a mean SI of 0.95  0.07 min
1 · U · ml1 · 104), and
atients with SI above the median value (n  53) had a mean
I of 4.08  0.40 min
1 · U · ml1 · 104. The main charac-
eristics of both groups are shown in Table 2. Both subgroups
ere similar in terms of age and NYHA functional class and
arameters of body composition (all p  0.2, except for arm
ean tissue [p 0.08] and BMI [p 0.06]), but patients with
I above the median value had a higher LVEF (p 0.02) and
eak VO2 (p  0.03).
A comparison of SI between NYHA functional classes in
HF patients and healthy control subjects is shown in Figure
. Control values were obtained from healthy subjects (mean
ge 54.6 years [range 32 to 74 years]) who voluntarily under-
ent metabolic assessment in our research unit. There was a
tepwise decrease of SI across NYHA functional classes, with
he lowest values in class IV (p  0.0007 by analysis of
ariance). In regression analysis, SI correlated with LVEF (r
.36), peak VO2 (r  0.23), BMI (r  0.22), and total (r 
With Chronic Heart Failure and Group Comparison Between
ere Alive at the End of the Follow-Up Period
Patients Who Died
(n  53)
Patients Alive
(n  52) p Value
64  1 60  2 0.09
33 (62%) 33 (63%)
20 (38%) 19 (37%) 0.9
2.8  0.1 2.3  0.1 0.003
112  3 120  3 0.03
70  2 74  2 0.09
16.1  0.9 20.3  1.0 0.004
394  26 454  34 0.17
26  2 31  3 0.19
137  0.5 138  0.4 0.04
147  9 110  7 0.002
531  22 413  17 <0.0001
13.2  0.23 13.6  0.17 0.28
5.15  0.15 5.10  0.17 0.8
71.0  2.1 76.8  2.3 0.06
24.2  0.7 25.2  0.6 0.27
16.9  1.2 20.0  1.2 0.07
9.58  0.75 11.1  0.59 0.13
6.38  0.52 7.84  0.59 0.06
1.60  0.07 1.51  0.58 0.3
50.6  1.13 54.4  1.48 0.04
21.0  0.53 23.4  0.69 0.005
105  4.4 103  4.7 0.7
14.0  1.37 12.0  1.25 0.2
4,707  526 3,443  320 0.04
1.87  0.24 3.21  0.43 0.002
esented as the mean value  SEM or number (%) of subjects. Bold values indicate
w York Heart Association; VO2  oxygen uptake.ents
ho W
are pr0.23) and regional fat mass (r  0.27; all p  0.05). No
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Insulin Resistance and Survival in CHF September 20, 2005:1019–26orrelation was found for SI versus age, mean arterial pressure,
ean tissue mass, serum cholesterol, creatinine, uric acid, or
emoglobin (all p  0.25).
Table 2. Group Comparison Between Patients
the Median Insulin Sensitivity Value (1.82 min
Parameter
B
Age (yrs)
Etiology
Ischemic cardiomyopathy
Dilated cardiomyopathy
NYHA functional class (mean)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Peak VO2 (ml/kg/min)
Exercise time (s)
LVEF (%)
Sodium (mmol/l)
Creatinine (mol/l)
Uric acid (mol/l)
Hemoglobin (g/dl)
Cholesterol (mmol/l)
Weight (kg)
Body mass index (kg/m2)
Total body fat tissue (kg)*
Central fat tissue (kg)*
Peripheral fat tissue (kg)*
Ratio central/peripheral fat*
Total lean tissue (kg)*
Fasting glucose (mg/dl)
Fasting insulin (mU/l)
Incremental insulin area (min · mU/l)
Insulin sensitivity (min1 · U · ml1 · 104)
*Dual-energy X-ray absorptiometric scan in 89 subjects (47
the mean value  SEM or number (%) of subjects. Bold va
Abbreviations as in Table 1.
igure 1. Insulin sensitivity in patients with chronic heart failure according
o New York Heart Association (NYHA) functional class, as compared
ith healthy control subjects. Box plot displaying the 10th, 25th, 50th,
5th, and 90th percentiles. The p values for the Fisher post-hoc test of
ean square-root transformed insulin sensitivity. *p  0.05 and **p 
.005 vs. controls.Insulin sensitivity was not significantly different between
atients treated with beta-blockers and those without (p 
.13). Similarly, no difference was found for SI between
atients with and without ACE inhibitor (p  0.38) and
iuretic treatment (p  0.49).
redictors of mortality. In univariate Cox proportional
azard analysis, a higher SI as a continuous variable signif-
cantly predicted lower mortality (RR 0.56, 95% CI 0.35 to
.89; p  0.015). Fasting glucose and insulin levels and
ncremental insulin area did not significantly predict mor-
ality (all p  0.3). Low SI also predicted impaired survival
fter adjustment for parameters of body composition, such
s BMI, total amount of fat tissue, and regional fat
istribution (p  0.01; data not shown). When adjusted for
he use of beta-blockers, ACE inhibitors, and diuretics, SI
emained a significant predictor of mortality (p  0.0080),
ith only diuretic treatment significantly contributing to
rognosis (p  0.018 vs. p  0.3 for ACE inhibitors and
eta-blockers). In addition, age, NYHA functional class,
nd peak VO2 as a continuous variable and as a dichoto-
ized variable (peak VO2 14 ml/kg/min), serum uric acid
all p  0.01), hemoglobin (p  0.018), fat tissue mass, and
ean tissue mass (both p  0.05) predicted mortality, but
VEF, BMI, and cholesterol did not (Table 3).
h Chronic Heart Failure Above and Below
U · ml1 · 104)
Patients
Median SI
 52)
CHF Patients
Above Median SI
(n  53) p Value
 1 61  2 0.5
(65%) 32 (60%)
(35%) 21 (40%) 0.6
 0.1 2.5  0.1 0.3
 3 116  3 0.9
 2 72  2 0.8
 1.0 19.7  1.0 0.031
 29 447  33 0.3
 2 33  3 0.019
 0.4 138  0.5 0.3
 9 117  8 0.06
 22 461  21 0.4
 0.23 13.5  0.18 0.3
 0.16 4.94  0.15 0.10
 2.5 71.9  1.8 0.2
 0.7 23.8  0.5 0.06
 1.3 17.1  1.1 0.2
 0.7 9.6  0.6 0.2
 0.6 6.47  0.5 0.15
 0.07 1.56  0.06 0.8
 1.4 52.0  1.2 0.7
 5 99  4 0.2
 1.47 9.76  0.91 0.0003
 482.4 2,726  309.0 <0.0001
 0.07 4.08  0.40 —
median SI and 42 above median SI). Data are presented as
dicate statistically significant results.Wit
1 ·
CHF
elow
(n
63
34
18
2.6
116
71
16.8
403
24
137
140
484
13.2
5.31
75.7
25.5
19.5
10.9
7.61
1.55
52.7
108
16.27
5,461
0.95
belowIn multivariate analysis including SI and clinical param-
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September 20, 2005:1019–26 Insulin Resistance and Survival in CHFters (age, NYHA functional class, peak VO2, mean arterial
ressure, uric acid, hemoglobin, cholesterol, sodium, creat-
nine, total fat tissue mass, lean tissue mass, and diuretic
reatment), SI remained a significant prognosticator, inde-
endent of all other parameters (RR 0.30, 95% CI 0.14 to
.63; p  0.0016). In stepwise Cox proportional hazards
nalysis in three multivariate cumulative models, SI was an
ndependent predictor of impaired survival (Table 4). The
ear of recruitment did not contribute to prediction of
Table 3. Univariate Cox Proportional Hazards
Parameter
Insulin sensitivity, continuous (min1 · U · ml1 · 1
Age (yrs)
NYHA functional class
Peak VO2 (continuous, ml/kg/min)
LVEF (%)
Mean arterial pressure (mm Hg)
Diuretic treatment
Sodium level (mmol/l)
Creatinine (mol/l)
Uric acid (mol/l)
Hemoglobin (g/dl)
Cholesterol (mmol/l)
Weight (kg)
BMI (kg/m2)
Total body fat tissue (kg)
Central fat tissue (kg)
Peripheral fat tissue (kg)
Total body lean tissue (kg)
Body composition data by dual-energy X-ray absorptiometr
results.
BMI  body mass index; CI  confidence interval; RR
able 4. Stepwise Cox Proportional Hazard Analysis in Patients
Parameter
Model 1
RR 95% CI p Value
nsulin sensitivity, continuous
(min1 · U · ml1 · 104)
0.38 0.21–0.67 0.001
ge (yrs) 1.06 1.026–1.093 <0.001
ean arterial pressure (mm Hg) 0.96 0.94–0.99 0.008
YHA functional class 0.2
eak VO2 (continuous, ml/kg/min) 0.14
MI 0.07
tiology 0.15
iuretic treatment 0.7
CE inhibitor treatment 0.9
eta-blocker treatment 0.16
ric acid (mol/l)
reatinine (mol/l)
emoglobin (g/dl)
odium level (mmol/l)
otal body fat tissue (kg)
entral fat tissue
eripheral fat tissue (kg)
otal body lean tissue (kg)
linical variables (model 1), biochemical variables (model 2), and body compositio
ual-energy X-ray absorptiometric scan in 89 patients. In respective analysis using SI
R 0.21 (95% CI 0.14–0.52); model 2: RR 0.24 (95% CI 0.12–0.49); model 3: RR 0.24 (9
ACE  angiotensin-converting enzyme; other abbreviations as in Tables 1 and 3.urvival in either univariate or multivariate analyses (data
ot shown).
By analyzing SI as a dichotomized variable, it was found
hat patients with SI above the median value had better
urvival than did patients with SI below the median value
RR 0.38, 95% CI 0.21 to 0.67; p  0.001). At two years,
urvival of patients with SI above the median was 83%
range 73% to 93%), but in patients with SI below the
edian, it was 61% (range 47% to 74%). At three years,
lyses in Patients With Chronic Heart Failure
Univariate Analysis
RR (95% CI) p Value
0.56 (0.35–0.89) 0.015
1.04 (1.01–0.07) 0.0066
1.62 (1.16–2.26) 0.006
0.92 (0.87–0.97) 0.0003
0.98 (0.96–1.01) 0.18
0.96 (0.94–0.99) 0.003
0.21 (0.051–0.85) 0.029
0.89 (0.83–0.97) 0.0089
1.006 (1.003–1.01) 0.0003
1.004 (1.003–1.006) 0.0001
0.76 (0.61–0.95) 0.018
0.87 (0.66–1.15) 0.3
0.97 (0.96–0.99) 0.013
0.94 (0.88–1.01) 0.07
0.95 (0.91–0.99) 0.013
0.91 (0.85–0.99) 0.026
0.88 (0.80–0.97) 0.014
0.96 (0.93–0.99) 0.028
in 89 patients. Bold values indicate statistically significant
ratio; other abbreviations as in Table 1.
Chronic Heart Failure
Model 2 Model 3
R 95% CI p Value RR 95% CI p Value
.33 0.17–0.65 0.001 0.28 0.14–0.55 0.0003
.065 1.026–1.11 0.001 1.068 1.029–1.11 0.0006
0.06 0.3
0.2 0.17
0.8 0.5
0.3 0.6
0.6 0.8
0.8 0.5
0.3 0.2
0.5 0.9
.003 1.001–1.005 0.001 1.003 1.001–1.005 0.0017
.005 1.000–1.01 0.038 0.09
0.11 0.3
0.3 0.6
0.95 0.90–0.99 0.036
0.7
0.4
0.8
ables (model 3) were tested in a cumulative approach. Body composition data by
hotomized variable (above/below median), the following was found for SI: model 1:Ana
04)
ic scanWith
R
0
1
1
1
n vari
as dic5% CI 0.11–0.50); all p  0.001. Bold values indicate statistically significant results.
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0% to 58%), and at four years, survival was 73% (range
0% to 85%) and 37% (range 23% to 51%), respectively
Fig. 2). For illustrative purposes, the prognostic signif-
cance of the combination of SI and peak VO2 used as
ichotomized variables in a two-risk factor model is
hown in Figure 3.
ISCUSSION
his study shows that impaired SI in patients with CHF is
ndependently associated with impaired prognosis. Insulin
esistance provides additional prognostic information inde-
endent of well-established prognosticators, such as clinical
tatus, age, LVEF, and exercise capacity, as well as body
omposition measures. It has previously been shown from
ur group (3) and others (2) that insulin resistance occurs in
HF independent of ischemic etiology and is associated
ith the severity of CHF in terms of reduced peak VO2 (1),
YHA functional class, or the 6-min walk test (11). In the
resent study, SI decreases in parallel with the severity of
HF, as indicated by a stepwise reduction with higher
YHA functional classes.
Insulin resistance is a key precursor and feature of type 2
iabetes. Therefore, information on type 2 diabetes and
HF may provide indirect information on the clinical
ignificance of insulin resistance in CHF (although insulin
eficiency may also be a factor in any association between
ype 2 diabetes and CHF). Diabetes mellitus is a major
igure 2. Survival in stable, ambulatory chronic heart failure patients (n 
05), classified according to the degree of impairment of insulin sensitivity
SI) (i.e., above [n  53] or below [n  52] median SI of 1.82
in1 · U · ml1 · 104). Kaplan-Meier survival curve for four-year
urvival.o-morbidity in patients with CHF, with a prevalence of
r
K0% to 25% (7–10). The Framingham study was the first to
how that diabetes mellitus is an independent risk factor for
eart failure with a 2.4 times higher risk in men and a 5.1
imes higher risk in women, as compared with those
ithout diabetes (18). In more recent, large epidemiologic
tudies, this association has been confirmed (4,5). In CHF,
iabetes independently predicts all-cause mortality in both
ymptomatic and asymptomatic heart failure patients (RR
.29, p 0.002), as well as hospitalization due to CHF (RR
.52, p  0.001) (6). A reciprocal relationship emerges
etween CHF and type 2 diabetes that suggests impaired SI
eing a significant pathophysiologic factor in the metabolic
mbalance of the heart failure syndrome. Notably, type 2
iabetes mellitus is only the late consequence of insulin
esistance, with the latter preceding frank diabetes for years
f not decades (19). The prevalence of diabetes mellitus in
HF, therefore, provides only a minimum indicator of the
rue prevalence of insulin resistance in these patients.
ccordingly, an analysis from the Randomized Evaluation
f Strategies for Left Ventricular Dysfunction (RESOLVD)
ilot study has shown that, based on fasting blood glucose
riteria, 43% of patients had abnormal glucose metabolism
11).
The present study is in line with previous data by Paolisso
t al. (20), who observed impaired SI as a prognostic marker
n CHF. However, in their study, Paolisso at al. (20)
xcluded about 50% of deaths from their mortality analysis
igure 3. Survival in stable, ambulatory chronic heart failure patients in a
wo-risk factor model using insulin sensitivity (SI) and peak oxygen uptake
VO2) as dichotomized variables: interaction of impaired SI (below median
f 1.82 min1 · U · ml1 · 104), with the presence of low peak VO2 (peak
O2 14 ml/kg/min) (patients with no risk factor: n  41, 6 deaths; oneisk factor: n  44, 23 deaths; two risk factors: n  20, 15 deaths).
aplan-Meier survival curve for four-year survival.
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September 20, 2005:1019–26 Insulin Resistance and Survival in CHFs non-cardiac events. This might have had the effect of
nderestimating true mortality in their cohort. Moreover,
atients with BMI 28 kg/m2 were excluded from this
tudy, which may restrict applicability for the general CHF
opulation (21).
Impaired SI is commonly known to relate to increased
MI, as obesity is a common confounder of type 2 diabetes.
ccordingly, we found a correlation between SI and BMI
nd fat tissue mass. In our study, however, CHF patients
ith lower versus higher SI were not significantly different
n terms of body composition. Moreover, when comparing
he patients who died with those who were alive at the end
f the follow-up period, SI was 42% lower in the patients
ho died. These patients were not heavier than the patients
ho survived, neither did they have more fat or lean tissue.
n fact, the surviving patients (i.e., those with a greater SI)
ad a tendency toward a higher fat tissue mass. This is
onsistent with a previous observation of high BMI being a
urvival advantage in CHF (22,23). In our study, low SI
redicted impaired survival independent of parameters of
ody composition, such as weight, BMI, and total and
egional fat, as well as lean tissue mass. This is in contrast to
he expected association between insulin metabolism and
ody composition (see above). In CHF patients, impaired SI
s not merely a function of adiposity and may indeed have
mplications in the pathophysiology of CHF disease pro-
ression. Our study confirms and extends previous data
howing that the abnormalities in SI in CHF may occur
econdary to heart failure itself (1). Our data also suggest
hat in CHF, factors causing impaired balance between
etabolic pathways and body composition might supersede
he physiologic feedback regulation between the aforemen-
ioned factors.
To establish the underlying mechanism(s) of insulin
esistance in these patients is beyond the scope of this study.
ikely, a number of factors, exerting a combined effect, may
ave contributed, such as reduced peripheral tissue perfu-
ion, impaired oxidative metabolism, lower GLUT4 trans-
ort protein amount in skeletal muscle (24), and increased
euroendocrine and immune activation (20). Moreover,
hanges in diet and reduced physical exercise may be
iscussed. Beta-blocker treatment has previously been re-
orted to worsen metabolic control, but recent evidence
uggests a beneficial effect of carvedilol on SI in hypertensive
ype 2 diabetics (25). Data on the metabolic effects of
arvedilol in CHF are, however, inconclusive, as studies
ith no effect on glucose utilization in CHF have been
eported (26,27). In our study population, SI was not
ependent on treatment with beta-blockers, diuretics, or
CE inhibitors. When adjusting the Cox model for treat-
ent, SI remained a significant predictor of mortality. The
se of beta-blockers in the present study was low, however,
nd more work is needed to evaluate the effect of medica-
ions such as carvedilol on SI in CHF. Although medical
reatment standards have advanced during the prolonged
ecruitment period, the predictive value of SI on survival wasot altered when adjusted for the year of recruitment.
hether more complete adherence to modern treatment
tandards may improve SI in CHF needs to be tested in the
uture. Insulin sensitivity is not commonly assessed in
atients with CHF during the routine clinical outpatient
ollow-up and is recognized only when overt diabetes
ellitus is diagnosed. The aim of the present study has not
een to establish SI assessment by minimal modeling as
nother marker for prognostic evaluation in CHF, but to
mphasize the importance of metabolic derangement con-
ributing to CHF pathophysiology, which only recently has
een gathering growing attention. The time-consuming
ssessment of SI by ivGTT may render this method unsuit-
ble to large epidemiologic studies. Simple and easier to
pply estimates of SI such as homeostasis model assessment
using a single time point assessment) may provide a
easonable estimate in large-scale studies. In the setting of
maller epidemiologic evaluations such as the current study,
owever, the dynamic assessment of SI within the physio-
ogic range of glucose metabolism may provide a more
horough estimate of pathophysiologic processes.
From the present data, it seems promising to test in
uture studies whether early detection and therapeutic tar-
eting of insulin resistance in CHF may improve the
utcome in these patients. This is indirectly supported from
ata from long-term exercise studies that show a reduction
f mortality in CHF (28,29). Arguably, the well-known
eneficial effect of physical exercise on SI (30) may be
nvolved in the physiologic mechanisms that underlie the
eneficial effects of exercise in CHF patients. Whether drug
herapy aimed at improved SI may have a comparable
eneficial effect is not known. Thiazolidinediones are selec-
ive agonists of peroxisome proliferator-activated receptor-
amma modulating, on a transcriptional level, the insulin-
ediated glucose utilization by the skeletal muscle. Insulin
ensitizers are, however, controversial in patients with CHF,
s they increase fluid retention and may contribute to
ncreased edema in CHF. Interventional studies designed to
est whether targeting impaired SI may be beneficial in
atients with CHF are required but need to be done
arefully and with great attention to potential adverse
ffects.
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